FDA OK's Xolair in chronic idiopathic urticaria
This article was originally published in Scrip
Executive Summary
The US FDA on 21 March approved Genentech's supplemental biologics license application (sBLA) to expand the use of Xolair (omalizumab) as a treatment for chronic idiopathic urticaria (CIU), a skin condition characterized by red, swollen, itchy hives.